Kelsen J, Agnholt J, Falborg L, Nielsen J T, Rømer J L, Hoffmann H J, Dahlerup J F
Department of Medicine V, Aarhus University Hospital, Denmark.
Clin Exp Immunol. 2004 Oct;138(1):66-74. doi: 10.1111/j.1365-2249.2004.02578.x.
Integrin alpha4beta 7 is the principal gut-homing receptor, and it is assumed that expression of this specific integrin directs lymphocytes to the gut in vivo. Adoptive cellular immunotherapy against inflammatory bowel disease (IBD) may depend on the expression of integrin alpha4beta 7 to accomplish local delivery of intravenously injected regulatory T cells in inflamed gut mucosa. The present study aimed to investigate whether in vitro expanded human T cells from the colonic mucosa maintain integrin expression, show in vitro adhesion and retain in vivo gut-homing properties during cultivation. Whole colonic biopsies from healthy subjects were cultured in the presence of interleukin-2 (IL-2) and IL-4. The integrin expression of the cultured T cells was determined by flow cytometry and in vitro adhesion was assessed in a mucosal addressin cell adhesion molecule 1 (MAdCAM-1) adhesion assay. We studied the homing pattern after autologous infusion of 3 x 10(8 111)Indium ((111)In)-labelled T cells in five healthy subjects using scintigraphic imaging. The cultured CD4(+)CD45RO(+) gut-derived T cells express higher levels of integrin alpha4beta 7 than peripheral blood lymphocytes (PBLs) and show strong adhesion to MAdCAM-1 in vitro, even after (111)In-labelling. Scintigraphic imaging, however, showed no gut-homing in vivo. After prolonged transit through the lungs, the T cells migrated preferentially to the spleen, liver and bone marrow. In conclusion, it is feasible to infuse autologous T cells cultured from the gut mucosa, which may be of interest in adoptive immunotherapy. Despite high expression of the gut-homing integrin alpha4beta 7 and adhesion to MAdCAM-1 in vitro, evaluation by (111)In-scintigraphy demonstrated no gut-homing in healthy individuals.
整合素α4β7是主要的肠道归巢受体,据推测这种特定整合素的表达在体内可引导淋巴细胞至肠道。针对炎症性肠病(IBD)的过继性细胞免疫疗法可能依赖于整合素α4β7的表达,以实现静脉注射的调节性T细胞在炎症肠道黏膜中的局部递送。本研究旨在调查从结肠黏膜体外扩增的人T细胞在培养过程中是否维持整合素表达、表现出体外黏附能力并保留体内肠道归巢特性。将来自健康受试者的全结肠活检组织在白细胞介素-2(IL-2)和IL-4存在的情况下进行培养。通过流式细胞术测定培养的T细胞的整合素表达,并在黏膜地址素细胞黏附分子1(MAdCAM-1)黏附试验中评估体外黏附能力。我们使用闪烁成像研究了5名健康受试者自体输注3×10⁸铟(¹¹¹In)标记的T细胞后的归巢模式。培养的CD4⁺CD45RO⁺肠道来源T细胞比外周血淋巴细胞(PBLs)表达更高水平的整合素α4β7,并且即使在¹¹¹In标记后,在体外也对MAdCAM-1表现出强烈黏附。然而,闪烁成像显示在体内没有肠道归巢。在长时间通过肺部后,T细胞优先迁移至脾脏、肝脏和骨髓。总之,输注从肠道黏膜培养的自体T细胞是可行的,这在过继性免疫疗法中可能具有意义。尽管肠道归巢整合素α4β7在体外高表达且对MAdCAM-1有黏附,但¹¹¹In闪烁扫描评估显示在健康个体中没有肠道归巢。